Biohaven Ltd. (BHVN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.31 (+3.01%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Biohaven Ltd. (BHVN)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Key Insights

Critical company metrics and information
  • Share Price

    $44.80
  • Market Cap

    $4.53 Billion
  • Total Outstanding Shares

    101.12 Million Shares
  • Total Employees

    239
  • Dividend

    No dividend
  • IPO Date

    September 23, 2022
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.biohavenpharma.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-154.30 Million
Net Cash Flow From Financing Activities, Continuing$80.38 Million
Net Cash Flow From Investing Activities, Continuing$-93.40 Million
Exchange Gains/Losses$0.00
Net Cash Flow From Financing Activities$80.38 Million
Net Cash Flow From Operating Activities$-141.28 Million
Net Cash Flow$-154.30 Million
Net Cash Flow From Operating Activities, Continuing$-141.28 Million
Net Cash Flow From Investing Activities$-93.40 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Basic Average Shares$94.37 Million
Income/Loss From Continuing Operations After Tax$-160.30 Million
Operating Income/Loss$-178.17 Million
Income Tax Expense/Benefit$59000.00
Net Income/Loss$-160.30 Million
Diluted Earnings Per Share$1.70
Diluted Average Shares$94.37 Million
Revenues$0.00
Income/Loss From Continuing Operations Before Tax$-160.36 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Available To Common Stockholders, Basic$-160.30 Million
Basic Earnings Per Share$1.70
Net Income/Loss Attributable To Parent$-160.30 Million
Nonoperating Income/Loss$17.80 Million
Costs And Expenses$178.17 Million
Research and Development$157.61 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Noncurrent Assets$70.02 Million
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$194.52 Million
Assets$510.52 Million
Other Current Assets$385.33 Million
Intangible Assets$18.40 Million
Current Liabilities$152.29 Million
Other Current Liabilities$116.67 Million
Accounts Payable$19.74 Million
Wages$15.88 Million
Other Non-current Assets$33.35 Million
Current Assets$440.50 Million
Prepaid Expenses$55.17 Million
Equity$316.01 Million
Equity Attributable To Parent$316.01 Million
Noncurrent Liabilities$42.22 Million
Liabilities And Equity$510.52 Million
Fixed Assets$18.28 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.